-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumor necrosis factor (TNF) inhibitors represented by infliximab can treat many chronic immune- mediated inflammatory diseases, such as rheumatoid arthritis , spondyloarthritis, psoriatic arthritis, medsci.
Immune Rheumatoid Arthritis and medsci.
The study was carried out in 21 Norwegian hospitals.
The average age of the patients was 44.
100 of the 198 patients in the TDM group (50.
For patients with immune-mediated inflammatory diseases treated with infliximab, compared with standard treatment, the active therapeutic drug monitoring program did not significantly improve the clinical remission rate of patients within 30 weeks .
For patients with immune-mediated inflammatory diseases treated with infliximab, compared with standard treatment, the active therapeutic drug monitoring program did not significantly improve the clinical remission rate of patients within 30 weeks .
Original source
Silje Watterdal Syversen et al.
com/journals/jama/article-abstract/2779549" target="_blank" rel="noopener">Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial.
JAMA
Leave a message here